Sural Flap Use for the Treatment of Wounds With Underlying Osteomyelitis: Graft Size a Predictor in Outcome, a Systematic Review. Issue 6 (December 2017)

• Record Type: Journal Article
• Authors: Persaud, Sham; Chesser, Anthony; Pereira, Ryan; Ross, Adrianne
• Is Part Of: Foot & ankle specialist. Volume 10:Issue 6(2017:Dec.)
• Page Start: 560
• Page End: 566
• Publication Date: 2017-12
• Subjects: fasciocutaneous -- flap size -- osteomyelitis -- sural -- wound; Podiatry -- Periodicals; Orthopedics -- Periodicals; Foot -- Diseases -- Periodicals; Foot -- Surgery -- Periodicals; Ankle -- Surgery -- Periodicals; 617.585
• DOI: 10.1177/1938640017729496
• Languages: English
• ISSNs: 1938-6400

Abstract

The sural flap procedure is a versatile technique that can be used to cover many types of defects about the lower extremity. The management of soft tissue defects of the lower extremity with underlying osteomyelitis is difficult. The goal for any of these patients is to create a biomechanically stable foot for weight-bearing purposes with no continued infection. Data were gathered using multiple databases from the years 2000 to 2016. Data were compiled looking at the number of subjects, age, comorbidities, number of complications, number of failures, and average flap size of complications/failures. A total of 110 patients were gathered using 5 separate articles. Twenty-two of the 110 patients had short-term complications. Flap failure was seen in 9/110 patients. A significant difference was noticed in flap size between flap failure and complication groups and nonfailure groups. The average flap size of patients who had some form of complication or failure was 51.87 cm 2 in size. The average graft size for patients without complications during their recovery was 36.54 cm 2 . Within our study, the failure rate of 8.9% and complication rate of 13.7% are consistent with previous reports on sural perforator flaps. Last, with regard to the effect of flap size, there were significant differences between patients with a successful outcome and those who experienced complications or failures. Levels of Evidence: Therapeutic, Level III: Systematic review